Post-earnings recap
Reported
Thu, Feb 4, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
AstraZeneca reported a better-than-expected EPS for Q4 2015, but the stock fell by 5.9% in reaction. The lack of revenue data and guidance may have contributed to investor uncertainty, leading to the decline in stock price despite the EPS beat.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.94 | N/A | +6.82% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.